# \[e-drug\] Final Announcement Pharmacoepidemiology & Drug Safety Feb 8-12, 2016

**URL:** <https://talk.edrugplus.org/t/e-drug-final-announcement-pharmacoepidemiology-drug-safety-feb-8-12-2016/42411>\
**Category:** e-drug\
**Created:** [January 19, 2016, 6:23am UTC](https://talk.edrugplus.org/t/e-drug-final-announcement-pharmacoepidemiology-drug-safety-feb-8-12-2016/42411 "2016-01-19T06:23:39Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![rahul\_sharma](https://avatars.discourse-cdn.com/v4/letter/r/df705f/32.png) [@rahul\_sharma](https://talk.edrugplus.org/u/rahul_sharma)\
**Post date:** [January 19, 2016, 6:23am UTC](https://talk.edrugplus.org/t/e-drug-final-announcement-pharmacoepidemiology-drug-safety-feb-8-12-2016/42411/1 "2016-01-19T06:23:39Z")

</div>

E-DRUG: Final Announcement Pharmacoepidemiology & Drug Safety Feb 8-12, 2016  
-------------------------------------------------------------------------------------------------------

About the Programme

The Programme is designed to strengthen participants with concepts and  
current practices in Pharmacoepidemiology which will further enhance the  
intelligence and information dissemination on topics closely related to  
Pharmacoepidemiology, Pharmacovigilance, Adverse drug reactions, Public  
health, Epidemiologic methods, Medication adherence and Drug Pharmacoepidemiological

Studies offer assessment of potential short and long-run adverse drug events within the population.  
Pharmacoepidemiological information into action, describe and analyze the economics of drug use and to advise decision-makers.

PROGRAMME CONTENTS

&nbsp;&nbsp;&nbsp;- Design, results, analysis and interpretation of post-marketing  
&nbsp;&nbsp;&nbsp;surveillance and other studies looking at specific drugs, populations and  
&nbsp;&nbsp;&nbsp;outcomes;  
&nbsp;&nbsp;&nbsp;- Methods for detection and evaluation of drug-associated adverse  
&nbsp;&nbsp;&nbsp;events, Pharmacovigilance;  
&nbsp;&nbsp;&nbsp;- Assessments of risk and benefit in drug therapy;  
&nbsp;&nbsp;&nbsp;- Patterns of drug utilization;  
&nbsp;&nbsp;&nbsp;- Relationships between Pharmacoepidemiology and the formulation and  
&nbsp;&nbsp;&nbsp;interpretation of regulatory guidelines;  
&nbsp;&nbsp;&nbsp;- Risk management plans and programmes relating to pharmaceuticals,  
&nbsp;&nbsp;&nbsp;biologics and medical devices.

The programme will be organized in IIHMR University, Jaipur which is ranked  
No. 1 B-School in Health Sector in India (Outlook Magazine).

The institute has been designated as WHO collaborating Center for District Health Systems  
based on Primary Health Care. The Ministry of Health and Family Welfare, Government of India has identified the institute as an Institute of Excellence for training and capacity building.

For more details please go through the Brochure

\<[https://drive.google.com/file/d/0By4H6jhT35mtTE4ydUlNRFdZVlE/view?usp=sharing&gt](https://drive.google.com/file/d/0By4H6jhT35mtTE4ydUlNRFdZVlE/view?usp=sharing&gt);  
or  
contact on mobile +91 8058829298,  
or email \<rahulsharma@iihmr.edu.in\>  
or official web site  
\<[http://iihmr.edu.in/trainings&gt](http://iihmr.edu.in/trainings&gt);

With regards,  
Rahul Sharma  
Assistant Professor  
The IIHMR University,  
Rajashtan, India  
[https://www.iihmr.edu.in](https://www.iihmr.edu.in)  
Email: rahulsharma@iihmr.edu.in  
rahulsharma1in@gmail.com